A scan study of PSMA in glioblastoma during bevacizumab treatment
Original title: The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase is listed, so this is still a study and not regular care.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study uses a special scan to look at brain tumors in people taking bevacizumab.
Who this trial is for. This trial is for people with IDH wildtype glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary who are getting bevacizumab. Bevacizumab blocks VEGF, and everyone in the study gets PSMA scans.
Where it stands. This trial has not reported results. It is looking at PSMA in glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary and how PSMA relates to VEGF. The answer is not in yet.
What this means, and what it doesn't
What it could mean: This study may help doctors learn more about how these tumors behave. Someone who fits this picture could ask their care team about it.
What it doesn't mean: This does not mean the scan helps you. A trial is a test, not a proven treatment. Joining a trial is not a promise of benefit, and it is not a cure.
Source: ClinicalTrials.gov, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.